Taconic Biosciences Adds New Humanized Immune System (HIS) Model to Its Portfolio For Immuno-Oncology Research

New huNOG-EXL EA Model Extends Study Windows Significantly RENSSELAER, N.Y., Jan. 18, 2022 (GLOBE NEWSWIRE) — Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces the launch of the huNOG-EXL EA (Early Access) humanized immune system (HIS) mouse. This product expands Taconic’s widely used HIS portfolio. huNOG-EXL EA significantly lengthens the […]

New huNOG-EXL EA Model Extends Study Windows Significantly

RENSSELAER, N.Y., Jan. 18, 2022 (GLOBE NEWSWIRE) — Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces the launch of the huNOG-EXL EA (Early Access) humanized immune system (HIS) mouse. This product expands Taconic’s widely used HIS portfolio. huNOG-EXL EA significantly lengthens the study window during which a myeloid-lineage HIS mouse model can be used successfully.

Taconic’s huNOG-EXL models support human myeloid and lymphoid cells, making these mice especially useful for immuno-oncology research and other immune-related applications. With the longest lifespan of any myeloid-supportive HIS model, the original huNOG-EXL model (now called huNOG-EXL SA, or Standard Access) has been successfully applied in preclinical drug discovery research since 2016. The huNOG-EXL SA model is provided after a quality control step at 10 weeks post-engraftment. Feedback from users suggests research applications requiring particularly long study timelines or importation into regions with long quarantine periods present experimental and logistical hurdles that can limit the utility of the Standard Access (SA) model.

The new huNOG-EXL EA model removes those challenges by providing access to huNOG-EXL mice soon after engraftment, extending the useful study window. This makes the huNOG-EXL EA ideal for engraftment of slow-growing tumors, longer treatment paradigms, or various study customizations. Early access to an extended myeloid lineage model is also advantageous to researchers who face model importation quarantines, which would otherwise consume a significant portion of the useful study window for these mice. Because the huNOG-EXL EA model is shipped before an engraftment QC step is possible, it is made using cells from donors previously validated to engraft well so as to reduce the risk of engraftment failures.

“The huNOG-EXL EA model meets critical scientific needs for investigators performing immuno-oncology research or studying other immune-related diseases,” said Dr. Michael Seiler, vice president of commercial products at Taconic. “After conducting extensive research and development, along with rigorous beta testing with several industry partners, Taconic is excited to now offer the new model and expand the usefulness of this unique humanized mouse.”

To learn more about Taconic’s huNOG-EXL EA model, please contact us at 1-888-TACONIC (888-822-6642) in the US, +45 70 23 04 05 in Europe, or email info@taconic.com.

About Taconic Biosciences, Inc.

Taconic Biosciences is a fully licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic provides the best animal solutions so that customers can acquire, custom-generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, microbiome, immuno-oncology mouse models, and integrated model design and breeding services, Taconic operates three service laboratories and six breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia and has global shipping capabilities to provide animal models almost anywhere in the world.

Media Contact:

Nancy J Sandy

CEO

608-332-6320

Nancy.Sandy@taconic.com

Previous Article

‫تقرير غارتنر يذكر شركة فار آي في دليل السوق 2021 لتوجيه وجدولة السيارات وتقنيات الميل الأخير للمرة الرابعة على التوالي

Next Article

VS Partners invested in the acquisition of DuPont Clean Technologies, expanding global impact investing portfolio

Related Posts

CGTN: ‘Poetry Sans Frontiers’ series embraces common humanity through poems

BEIJING, Jan. 2, 2022 /PRNewswire/ — The five-episode feature series “Poetry Sans Frontiers” was broadcast on CGTN’s multi-language channels and various new media platforms, embracing diversity and common humanity through poetry. “Bosom friends make distance disappear,” wrote Chinese poet Zhang Jiuling in Tang Dynasty (618-907). The series, launched in the six official languages of the […]

Amorepacific sets five sustainability management goals for 2030

The ‘2030 A MORE Beautiful Promise’ includes five goals set under two guiding pillars, ‘moving forward together with customers and society’ and ‘coexisting responsibly with nature’ SEOUL, South Korea, June 2, 2021 /PRNewswire/ — Amorepacific today announced ‘2030 A MORE Beautiful Promise’ – a set of sustainability management goals it aims to achieve by 2030. A total […]

‫ كاواي ايلاندس جمعت 2.4 مليون دولارًا في عملية بيع خاصة لعملات رمزية لدعم مشروعها القادم في عالم الأنيمي

رود تاون، جزر فيرجن البريطانية, 9 سبتمبر/ أيلول 2021 /PRNewswire/ — Kawaii Islands هو مشروع للعبة خيال جديدة نشأت من الشراكة الإستراتيجية بين Imba Games StudioوOraichain، وقد جمعت 2.4 مليون دولارًا لبناء جيل جديد من ألعاب الرسوم المتحركة المعتمدة على الرمز الفريد غير المتكرر (NFT) حيث يكون كل المستخدمين متصلين ويمكنهم المشاركة في اللعب أو إنشاء المحتوى […]